Abiopharma

Novanta Inc. Announces Pricing of $550,000,000 Tangible Equity Units Offering

Fulgent Reports Third Quarter 2025 Financial Results

Canopy Growth Communication - Canopy Growth Reports Second Quarter Fiscal 2026 Financial Results; Company Continues to Strengthen Financial Performance with Improving Adjusted EBITDA, Disciplined Cost Management, and a Stronger Balance Sheet

agilon health - agilon Announces Receipt of Notice of Non-Compliance with the NYSE Continued Listing Standards

Viridian Therapeutics, Inc. - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025

Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

agilon Announces Receipt of Notice of Non-Compliance with the NYSE Continued Listing Standards

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting